Australia seems poised to gain access to innovative medication for excess weight: Retatrutide. This new dual compound – targeting on both GLP-1 and GIP receptors – demonstrates significant results in international research, suggesting considerable drops in BMI. While regulatory clearance remains with Australian regulators, several Australians b